The New Pharmacovigilance Legislation Will Impact US And European Drug Manufacturers

The New Pharmacovigilance Legislation Will Impact US And European Drug Manufacturers

Main Category: Pharma Industry / Biotech Industry
Also Included In: Conferences
Article Date: 11 May 2012 - 5:00 PDT

email to a friend   printer friendly   opinions   <!-- rate article

Patient / Public:

Healthcare Prof:

The Pharmacovigilance Legislation Will Come into Effect in July

As the European Medicines Agency's new PV (pharmacovigilance) Legislation implementation date of July 2012 approaches, US and European pharmaceutical and biotech companies need to ask themselves if they are ready for the changes that lie ahead, says Paul Beninger, MD, FACP, Vice President, Global Patient Safety, Genzyme.

The goal of the PV Legislation is increased access to information and greater transparency of processes, in the wake of the French company Servier's Mediator scandal. Licensed as an add-on for hyperlipidaemia and diabetes, but used off-label for obesity, Mediator reportedly caused 500 to 2000 deaths in its 33 years on the market. The new legislation aims to prevent similar drug safety issues from lying undetected for so long.

"The implications of the PV Legislation are extensive, with implications for both US and European drug manufacturers," according to Beninger, a speaker at the upcoming marcus evans 2nd Global Pharmacovigilance Adverse Event Reporting Conference.

"Any company that has a European presence will need to integrate its processes and activities on the collection, monitoring and evaluation of information on the adverse effects of medications. The new legislation will replace Volume 9A of the rules governing medicinal products; that is how extensive the changes will be. Companies have spent the last 9 to 12 months preparing for it, but a full integration will require a lot more time."

US companies also need to be aware of the recent Investigational New Drug (IND) Final Rule, and the upcoming New Drug Application (NDA) Final Rule and manufacturing supply chain regulations. "Companies must take this very seriously and figure out a way to get adequate control of their supply chains," Beninger adds.

The Prescription Drug User Fee Act (PDUFA) is also up for changes by September 2012. Beninger noted: "We have a good idea of what it covers on the statutory level, but not at the regulatory level."

"There has been a paradigm shift from 'safe and effective' to 'benefit-risk' over the last decade in evaluating new medicinal products for human use, with emphasis now on risk-management: risk identification, risk assessment, risk mitigation and risk communication. All organisations now need to cover all of these functions, no matter their size.

"Companies should consider how audit ready they are. That has implications for many of their activities. Being audit ready is one of the most important responsibilities that the PV department has. It must be ready to answer any question that an auditor may have. This is more than just compliance, but about all of their processes. Companies need to ask themselves one question: Are they audit ready?" Beninger concludes.

The marcus evans 2nd Global Pharmacovigilance Adverse Event Reporting Conference will take place at Le Meridien Cambridge, Cambridge, MA, May 22-24, 2012.

For more information please contact Michele Westergaard, Marketing/PR Coordinator, marcus evans at 312-540-3000 ext. 6625 or Michelew@marcusevansch.com.

• Additional
• References
• Citations

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

---

APA

---

Please note: If no author information is provided, the source is cited instead.

---

Add Your Opinion On This Article

'The New Pharmacovigilance Legislation Will Impact US And European Drug Manufacturers'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.

back to top | home | privacy policy

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.